Detection of multiple cytokines in the urine of patients with focal necrotising glomerulonephritis may predict short and long term outcome of renal function

Cytokine

Volumn 57, Issue 1, 2012, Pages 120-126

  Stangou, Maria ^a   Papagianni, Aikaterini ^a   Bantis, Christos ^a   Liakou, Helen ^a   Pliakos, Kostas ^a   Giamalis, Panagiotis ^a   Gionanlis, Lazaros ^a   Pantzaki, Afroditi ^b   Efstratiadis, Georgios ^a   Memmos, Dimitrios ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Aristotle University and Hippokration General Hospital   (Greece)

Author keywords

Growth factors; Interleukins; Necrotising glomerulonephritis outcome; Urine

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOKINE; EPIDERMAL GROWTH FACTOR; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 9; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG DOSE REDUCTION; FEMALE; FOCAL GLOMERULONEPHRITIS; FOCAL SEGMENTAL NECROTIZING GLOMERULONEPHRITIS; FOLLOW UP; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY FUNCTION; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; TREATMENT RESPONSE; URINARY EXCRETION; URINE LEVEL;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; GLOMERULONEPHRITIS; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME;

EID: 84155163878     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2011.10.003     Document Type: Article

References (27)

1. Morgan M.D., Harper L., Williams J., Savage C. Anti-neutrophil cytoplasm-associated glomerulonephritis. J Am Soc Nephrol 2006, 17:1224-1234.
2. Segerer S., Nelson P.J., Schlondorff D. Chemokines, chemokine receptors, and renal disease: from basic science to pathophysiologic and therapeutic studies. J Am Soc Nephrol 2000, 11:152-176.
3. De Muro P., Faedda R., Fresu P., Masala A., Cigni A., Concas G., et al. Urinary transforming growth factor-beta 1 in various types of nephropathy. Pharmacology 2004, 49:293-298.
4. Ruth A.-J., Kitching R., Semple T., Tipping P., Holdsworth S. Intrinsic renal cell expression of CD40 directs Th1 effectors inducing experimental crescentic glomerulonephritis. J Am Soc Nephrol 2003, 14:2813-2822.
5. Tesch G.H. MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am J Physiol Renal Physiol 2008, 294:F697-F701.
6. Torres D.D., Rossini M., Manno C., Mattace-Raso F., D'Altri C., Ranieri E., et al. The ratio of epidermal growth factor to monocyte chemotactic peptide-1 in the urine predicts renal prognosis in IgA nephropathy. Kidney Int 2008, 73:327-333.
7. Macunluoĝlu B., Gökçe I., Atakan A., Demirci M., Ari{dotless} E., Topuzoĝlu A., et al. A comparison of different methods for the determination of glomerular filtration rate in elderly patients with chronic renal failure. Int Urol Nephrol 2011, 43:257-263.
8. Weiler M., Rogashev R., Einbinder T., Hausmann M., Kanetl J., Chaimovitz C., et al. Interleukin- 15, a leukocyte activator and growth factor, is produced by cortical tubular epithelial cells. J Am Soc Nephrol 1998, 9:1194-1201.
9. Fehniger T.A., Caligiuri M.A. Interleukin 15: biology and relevance to human disease. Blood 2001, 97:14-32.
10. Matsumoto K., Ohi H., Kanmatsuse K. Effects of interleukin-15 on vascular permeability factor release by peripheral blood mononuclear cells in normal subjects and in patients with minimal-change nephrotic syndrome. Nephron 1999, 82:32-38.
11. Rafei M., Wu J.H., Annabi B., Lejeune L., François M., Galipeau J.A. GMCSF and IL-15 fusokine leads to paradoxical immunosuppression in vivo via asymmetrical JAK/STAT signalling through the IL-15 receptor complex. Blood 2007, 109:2234-2242.
12. Lan H.Y., Nikolic-Paterson D.J., Mu W., Atkins R.C. Local macrophage proliferation in the pathogenesis of glomerular crescent formation in rat anti-glomerular basement membrane (GBM) glomerulonephritis. Clin Exp Immunol 1997, 110:233-240.
13. Eremina V., Sood M., Haigh J., Nagy A., Lajoie G., Ferrara N., et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003, 111:707-716.
14. Shimizu A., Masuda Y., Mori T., Kitamura H., Ishizaki M., Sugisaki Y., Fukuda Y. Vascular endothelial growth factor165 resolves glomerular inflammation and accelerates glomerular capillary repair in rat anti-glomerular basement membrane glomerulonephritis. J Am Soc Nephrol 2004, 15:2655-2665.
15. Chen S., Jim B., Ziyadeh F.N. Diabetic nephropathy and transforming growth factor-beta: transforming our view of glomerulosclerosis and fibrosis build-up. Semin Nephrol 2003, 23:532-543.
16. Goumenos D.S., Tsamandas A.C., Oldroyd S., Sotsiou F., Tsakas S., Petropoulou C., et al. Transforming growth factor-beta(1) and myofibroblasts: a potential pathway towards renal scarring in human glomerular disease. Nephron 2001, 87:240-248.
17. Stangou M., Bhangal G., Lai P.-C., Smith J., Keith J.C., Boyle J.J., Pusey C.D., Cook T., Tam F.W. Effect of IL-11 on glomerular expression of TGF-beta and extracellular matrix in nephrotoxic nephritis in Wistar Kyoto rats. J Nephrol 2010, 24:106-111.
18. Wilkins-Port C.E., Higgins P.J. Regulation of extracellular matrix remodeling following transforming growth factor-beta1/epidermal growth factor-stimulated epithelial-mesenchymal transition in human premalignant keratinocytes. Cells Tissues Org 2007, 185:116-122.
19. Yang Y., Hou Y., Wang C.L., Ji S.J. Renal expression of epidermal growth factor and transforming growth factor-beta1 in children with congenital hydronephrosis. Urology 2006, 67:817-822.
20. Kelly D.J., Cox A.J., Tolcos M., Cooper M.E., Wilkinson-Berka J.L., Gilbert R.E. Attenuation of tubular apoptosis by blockade of the renin-angiotensin system in diabetic Ren-2 rats. Kidney Int 2002, 61:31-39.
21. Kishimoto T. IL-6: from its discovery to clinical applications. Int Immunol 2010, 22:347-352.
22. Abe M., Yokoyama Y., Syuto T., Ishibuchi H., Ishikawa O. Interleukin-6 counteracts effects of cyclosporin A on extracellular matrix metabolism by human dermal fibroblasts. Cell Tissue Res 2008, 333:281-288.
23. Kim J.H., Ha I.S., Hwang C.I., Lee Y.J., Kim J., Yang S.H., et al. Gene expression profiling of anti-GBM glomerulonephritis model: the role of NF-kappaB in immune complex kidney disease. Kidney Int 2004, 66:1826-1837.
24. Stangou M., Alexopoulos E., Papagianni A., Pantzaki A., Bantis C., Dovas S., et al. Urinary levels of epidermal growth factor, interleukin-6 and monocyte chemoattractant protein-1 may act as predictor markers of renal function outcome in immunoglobulin A nephropathy. Nephrology 2009, 14:613-620.
25. Stangou M., Alexopoulos E., Bantis C., Papagianni A., Giamalis P., Liakou H., et al. Differentiation between minimal change disease (MCD) and focal segmental glomerulonephritis (FSGS) based on urinary Epidermal Growth Factor (EGF) levels. NDT Plus 1 2008, 1(Suppl. 2).
26. Liu R., Zhou Q., La Cava A., Campagnolo D.I., Van Kaer L., Shi F.D. Expansion of regulatory T cells via IL-2/anti-IL-2 mAb complexes suppresses experimental myasthenia. Eur J Immunol 2010, 40:1577-1589.
27. Eller K., Wolf D., Huber J.M., Metz M., Mayer G., McKenzie A.N., et al. IL-9 production by regulatory T cells recruits mast cells that are essential for regulatory T cell-induced immune suppression. J Immunol 2011, 186:83-91.